Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Aduro Biotech (ADRO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 323,952
  • Shares Outstanding, K 79,404
  • Annual Sales, $ 17,240 K
  • Annual Income, $ -91,860 K
  • 36-Month Beta 1.89
  • Price/Sales 19.89
  • Price/Cash Flow N/A
  • Price/Book 1.94

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.23
  • Number of Estimates 5
  • High Estimate -0.10
  • Low Estimate -0.31
  • Prior Year -0.35
  • Growth Rate Est. (year over year) +34.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.34 +74.79%
on 01/29/19
4.38 -6.62%
on 02/15/19
+1.38 (+50.92%)
since 01/22/19
3-Month
2.34 +74.79%
on 01/29/19
4.38 -6.62%
on 02/15/19
+1.27 (+45.04%)
since 11/21/18
52-Week
2.34 +74.79%
on 01/29/19
9.93 -58.79%
on 03/13/18
-2.11 (-34.03%)
since 02/22/18

Most Recent Stories

More News
What's in Store for Vericel (VCEL) This Earnings Season?

On Vericel's (VCEL) fourth-quarter conference call, investor focus will be on the sales figures of the company's two approved medicines -- MACI and Epicel.

CARA : 16.95 (+1.86%)
BDSI : 5.00 (+5.71%)
VCEL : 19.57 (+1.98%)
ADRO : 4.09 (+0.25%)
Will Difficult Comparison Hurt Bio-Rad's (BIO) Q4 Earnings?

Bio-Rad (BIO) apprehends a year-over-year decline in revenues within Life Sciences segment due to difficult comparison.

ACIU : 4.35 (-6.05%)
APTO : 1.99 (+3.11%)
BIO : 274.26 (-0.03%)
ADRO : 4.09 (+0.25%)
Aduro Biotech to Present at the 8th Annual SVB Leerink Global Healthcare Conference

Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, is scheduled to present at the 8 Annual SVB Leerink Global Healthcare...

ADRO : 4.09 (+0.25%)
Aduro Announces Changes to its Board of Directors

Aduro Biotech, Inc. (NASDAQ: ADRO) today announced the appointment of David H. Mack, Ph.D., President and CEO of PMV Pharmaceuticals, to its Board of Directors effective February 19, 2019. In addition,...

ADRO : 4.09 (+0.25%)
Will Hospice Strength Show on Amedisys' (AMED) Q4 Earnings?

An increased reimbursement of approximately $1 million has boosted Amedisys' (AMED) Hospice business.

ACIU : 4.35 (-6.05%)
APTO : 1.99 (+3.11%)
AMED : 128.84 (+1.68%)
ADRO : 4.09 (+0.25%)
What's in Store for Tandem Diabetes' (TNDM) Q4 Earnings?

Strong domestic sales along with the launch of the t:slim X2 Insulin Pump in select international markets are likely to drive Tandem Diabetes' (TNDM) Q4 earnings.

ACIU : 4.35 (-6.05%)
TNDM : 48.32 (-1.53%)
MASI : 128.88 (+0.05%)
ADRO : 4.09 (+0.25%)
What's in Store for Sangamo (SGMO) This Earnings Season?

On Sangamo (SGMO) Q4 conference call, investors will look into genome editing development and gene regulation technology platform, used for inventing genomic therapies to address unmet medical needs.

SGMO : 8.83 (+3.40%)
BDSI : 5.00 (+5.71%)
PFE : 42.96 (+1.95%)
ADRO : 4.09 (+0.25%)
The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna

The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna

CLDX : 5.92 (-1.17%)
CYTK : 7.28 (+0.97%)
AEZS : 4.13 (+2.48%)
BDSI : 5.00 (+5.71%)
ADRO : 4.09 (+0.25%)
Consolidated Research: 2019 Summary Expectations for The Trade Desk, Aduro Biotech, Walker & Dunlop, California Resources, Century Casinos, and Arsanis -- Fundamental Analysis, Key Performance Indications

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of The Trade Desk Inc. (NASDAQ:TTD),...

TTD : 197.73 (+31.39%)
CRC : 21.72 (+0.37%)
ASNS : 2.66 (-1.12%)
WD : 57.58 (+1.12%)
ADRO : 4.09 (+0.25%)
CNTY : 8.72 (+1.40%)
Will Aduro Biotech Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in Aduro Biotech.

ADRO : 4.09 (+0.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

See More Share

Trade ADRO with:

Business Summary

Aduro Biotech, Inc. is an immunotherapy company. The Company develops technology and vaccines for the treatment of cancer and mesothelin-expressing tumors. Its product pipeline includes CRS-207, ADU-623, ADU-214, ADU-741, CDN and STINGVAX which are in different clinical trial. Aduro Biotech, Inc. is...

See More

Key Turning Points

2nd Resistance Point 4.39
1st Resistance Point 4.24
Last Price 4.09
1st Support Level 3.94
2nd Support Level 3.79

See More

52-Week High 9.93
Fibonacci 61.8% 7.03
Fibonacci 50% 6.13
Fibonacci 38.2% 5.24
Last Price 4.09
52-Week Low 2.34

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar